237 related articles for article (PubMed ID: 21218756)
1. Effectiveness of proton pump inhibitors in the treatment of patients with endoscopic esophagitis.
Gashi Z; Haziri A; Berisha D; Zekaj S; Polloshka A; Bakalli A; Juniku A; Sadriu L
Med Arh; 2010; 64(6):362-4. PubMed ID: 21218756
[TBL] [Abstract][Full Text] [Related]
2. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
3. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
Kindt S; Imschoot J; Tack J
Dis Esophagus; 2011 Nov; 24(8):531-7. PubMed ID: 21418126
[TBL] [Abstract][Full Text] [Related]
5. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
6. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
Roorda AK; Marcus SN; Triadafilopoulos G
Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
[TBL] [Abstract][Full Text] [Related]
7. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
8. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
[TBL] [Abstract][Full Text] [Related]
9. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
Orlando RC; Monyak JT; Silberg DG
Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
[TBL] [Abstract][Full Text] [Related]
11. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
Aliment Pharmacol Ther; 2009 May; 29(9):959-66. PubMed ID: 19222417
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors in the management of gastroesophageal reflux disease.
Hrelja N; Zerem E
Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
[TBL] [Abstract][Full Text] [Related]
14. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
15. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!
Scarpignato C
Neurogastroenterol Motil; 2012 Aug; 24(8):697-704. PubMed ID: 22783985
[TBL] [Abstract][Full Text] [Related]
16. Obesity does not affect treatment outcomes with proton pump inhibitors.
Sharma P; Vakil N; Monyak JT; Silberg DG
J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
[TBL] [Abstract][Full Text] [Related]
17. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
[TBL] [Abstract][Full Text] [Related]
18. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.
Weijenborg PW; Cremonini F; Smout AJ; Bredenoord AJ
Neurogastroenterol Motil; 2012 Aug; 24(8):747-57, e350. PubMed ID: 22309489
[TBL] [Abstract][Full Text] [Related]
19. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
[TBL] [Abstract][Full Text] [Related]
20. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
DeVault KR
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
